Please assess the completion status of the following clinical trial:

Trial Title: Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* HIV infection~* CD4 count obtained within 45 days prior to study entry~* Karnofsky performance score \>=70 on at least one occasion within 45 days prior to study entry~* The following labs within 45 days prior to study entry:~  * hemoglobin \>8.0 g/dL~ * direct bilirubin \<2.5 x upper limit of normal (ULN)~ * alanine aminotransferase, ALT (SGPT) \<3 xULN~ * aspartate aminotransferase, AST (SGOT) \<3 xULN~ * platelet count \>=100,000 /mm\^3~* Willing to use acceptable forms of contraception for the duration of the study~* Written informed consent from participant or from parent or guardian, if applicable~* If on HAART, then the same regimen for at least 12 weeks prior to study entry with no change within 30 days prior to study entry. (This criterion was removed in Version 2.0 of the protocol.)~* HIV viral load obtained within 45 days prior to study entry (This criterion was removed in Version 2.0 of the protocol.)~Exclusion Criteria:~* Abnormal Pap test with confirmed biopsy results of cervical intraepithelial neoplasia (CIN) II or III or cervical cancer within 180 days prior to study entry~* Vulval intraepithelial neoplasia (VIN) II or III or cancer confirmed by biopsy results within 180 days prior to study entry~* Physician-diagnosed genital warts within 180 days prior to study entry~* Previous cervical dysplasia treatment, including loop electrosurgical excision procedure (LEEP), cervical cryotherapy, cone biopsy, and cervical laser vaporization within 180 days prior to study entry~* Use of any systemic antineoplastic or immunomodulatory treatment, systemic corticosteroids, investigational vaccines, interleukins, interferons, growth factors, or intravenous immunoglobulin (IVIG) within 45 days prior to study entry. Participants who had received standard of care (e.g., hepatitis B, influenza, and tetanus) vaccines were not excluded.~* Known allergy or hypersensitivity to yeast or any components of the vaccine or its formulation~* Current drug or alcohol use or dependence or any other condition that may interfere with study participation~* Serious illness requiring systemic treatment and/or hospitalization within 45 days prior to study entry~* Total hysterectomy. Participants who had undergone partial hysterectomy and had a cervix were not excluded.~* Hemophilia~* Currently on anticoagulation therapy other than acetylsalicylic acid~* Prior vaccination with an HPV vaccine~* Pregnant or breastfeeding

- Gender: FEMALE
- Minimum Age: 13 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Stratum A (Type: EXPERIMENTAL): Participants with screening CD4 count \>350 cells/mm\^3 received 0.5mL of quadrivalent HPV vaccine at baseline and Weeks 8 and 24.
- Stratum B (Type: EXPERIMENTAL): Participants with screening CD4 count \>200 to \<=350 cells/mm\^3 received 0.5mL of quadrivalent HPV vaccine at baseline and Weeks 8 and 24.
- Stratum C (Type: EXPERIMENTAL): Participants with screening CD4 count \<=200 cells/mm\^3 received 0.5mL of quadrivalent HPV vaccine at baseline and Weeks 8 and 24.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete